aXichem obtains a patent for the use of phenylcapsaicin in the treatment of leaky gut

| 1 september, 2022 | 0 kommentarer

aXichem AB (publ) (“aXichem”), that develops and markets analogue industrial compounds, has received a patent regarding the company’s natural analogue capsaicin, phenylcapsaicin, and variants of the product, as a substance for the treatment of leaky gut. The patent significantly contributes to aXichem’s patent portfolio and is commercially valuable, since it protects the company’s unique product in an area where phenylcapcaicin, in tests, has shown clear effectiveness.

Leaky gut means that the intestinal wall’s protective barrier has weakened and thus lets toxins and bacteria through into the bloodstream. Leaky gut carries the risk of a number of different medical conditions and has therefore received more and more attention in recent years, including in research into the connection between diet and gut health.

aXichem’s patent application is entitled ”Capsaicyns in the treatment of leaky gut”.

“I see great opportunities for phenylcapsaicin in products related to pharmaceutical applications. Thanks to the product showing a good effect in low doses, it is an interesting alternative. The patent is an important step for aXichem and it further strengthens our solid foundation for progress in the company’s core businesses as well as in future pharmaceutical areas”, says Torsten Helsing, CEO of aXichem.

aXichem has global patent protection for the molecule phenylcapsaicin, derivatives of phenylcapsaicin, the method of producing the main molecule and derivatives of the molecules. The patent application ”Capsaicyns in the treatment of leaky gut” was submitted in November 2020.

The information was submitted, through the care of the contact person, for publication on September 1, 2022, at 8:45 AM CEST.

Torsten Helsing, CEO, aXichem, Ph+46 70 686 33 55. Email: [email protected]

aXichem’s business idea is to develop, patent and market natural analogue industrial compounds. The Company primarily works with phenylcapsaicin a structural analogue of capsaicin with a wide range of applications, such as feed additives, nutrition and supplements, marine anti-fouling products and certain pharmaceutical areas. aXichem’s shares are listed on NASDAQ First North Growth Market under AXIC A. Certified Adviser: Redeye AB. Read more about the company at

Kategori: Marknadsnyheter

Om skribenten ()

Tanalys är en sajt för investerare som med teknisk analys vill förbättra sin trading. Tanalys erbjuder teknisk analys från flera ledande analytiker, samt nyheter och utbildningar.

Lämna ett svar

Din e-postadress kommer inte publiceras.